Lipoprotein(a) and the effect of alirocumab on coronary and non-coronary revascularization following acute coronary syndrome

Back

ESC Professional Premium Access

Lipoprotein(a) and the effect of alirocumab on coronary and non-coronary revascularization following acute coronary syndrome

Session: What’s new on lipids and diabetes in acute coronary syndrome

Topic: Pharmacotherapy

Speaker: Professor P. Steg (Paris, FR)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Professor Philippe Gabriel Steg

Hospital Bichat-Claude Bernard, Paris (France)

66 presentations

10 followers

5 more presentations in this session

Proprotein convertase subtilisin/kexin type 9 (PCSK9), platelet activation and interaction with the vascular endothelium: the impact of PCSK9 inhibition with evolocumab in acute coronary syndrome

Speaker: Doctor E. Ziogos (Baltimore, US)

Quality matters: low-density lipoprotein electronegativity but not quantity determines mortality risk in acute coronary syndromes

Speaker: Doctor S. Kraler (Baden, CH)

Glycated haemoglobin and the association with long-term survival among patients evaluated for stable angina - a prospective Norwegian cohort

Speaker: Doctor G. Svingen (Bergen, NO)

Cardioprotective effect of empagliflozin in acute myocardial infarction: the role of ketone bodies availability.

Speaker: Professor J. Badimon (New York, US)

Impact of chronic GLP-1 receptor agonist and SGLT-2 inhibitor therapy on in-hospital outcomes of patients with diabetes mellitus hospitalized with acute myocardial infarction.

Speaker: Doctor F. Trombara (Milan, IT)

Access the full session

What’s new on lipids and diabetes in acute coronary syndrome

Speakers: Professor P. Steg, Doctor E. Ziogos, Doctor S. Kraler, Doctor G. Svingen, Professor J. Badimon...

Access

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources